Gain detailed insights into the trading activity of Congress members for CryoPort on our government trades page. Stay updated on how elected officials are investing in CYRX.

CryoPort - Government Trades

CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

Movers

News

Intraday Update

Markets

Trading Ideas

BBIO

COIN

CYRX

FUFU

INSP

MOLN

MSTR

NVDA

SIRI

SMCI

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

Coinbase Photo by Useacoin on Shutterstock

Price Target

AAPL

BKNG

TXRH

Coinbase Global To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Friday

Image 3

Pre-Market Outlook

ADNT

BBAI

CTOS

EXPE

FTNT

OTEX

STEM

TRUP

Stem Reports Downbeat Results, Joins Sprout Social, Cloudflare And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Penny Stocks

Small Cap

HEAR

HOOD

LQDA

PERF

PLMR

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday.

Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick&#39;s Sporting Goods And Other Big Stocks Moving Higher On Thursday

Analyst Color

Equities

Downgrades

Analyst Ratings

General

KeyBanc Capital Markets analyst Paul Knight downgraded CryoPort, Inc (NASDAQ: CYRX) to 

CryoPort&#39;s Refrigeration Unit Is A Distraction From Core Business: Analyst Expects Divestiture

Earnings

Guidance

Health Care

AZTA

Cryoport Inc (NASDAQ: CYRX) shares are trading lower after the company released certain preliminary results for Q2 FY23 and updated its

Cryoport On See-Saw Of Expectations: Analysts Cut Price Targets, But Remain Bullish On Long-Term Return

Eurozone

Commodities

Global

CAMT

FWBI

JZXN

NKLA

VSAT

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Thursday.

The Dow traded up 0.15% to 34,397.80 while the NASDAQ rose 1.40% to 14,114.17. The S&amp;P 500, also rose, gaining, 0.71% to 4,504.12.

Crude Oil Rises 1.5%; PepsiCo Earnings Top Views

AULT

CVKD

CVNA

EDTX

ELOX

GBIO

GLMD

HCTI

HIVE

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

HYZN

JFIN

LGHL

MBRX

MLKN

NFTG

PPSI

RKLB

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SIFY

SNAL

SNPX

SSYS

SURG

SXTP

TGTX

TTOO

VINE

WULF

Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.

The Dow traded up 0.13% to 34,392.36 while the NASDAQ rose 0.97% to 14,054.23. The S&amp;P 500, also rose, gaining, 0.52% to 4,495.37.

Nasdaq Rises Over 100 Points; Delta Air Lines Posts Upbeat Results

New York Stock Exchange

Macro Economic Events

Econ #s

Economics

PANW

PLUG

Market Reacts To PPI Inflation Drop: 7 Stocks in the Spotlight Thursday

CryoPort Inc

U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
Shares of ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) fell sharply during Monday's session following sleep apnea data from Lilly.
Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral.
ResMed shares dipped 10.4% to $184.35 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares dipped 22.6% to $7.43.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement.</li>
<li>BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) dipped 19.2% to $22.11.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) fell 17.7% to $5.11. Shares of crypto stocks traded lower after Bitcon fell below $62,000.</li>
<li>Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) declined 15% to $136.88. Stifel analyst Jonathan Block maintained Inspire Medical Systems with a Hold and lowered the price target from $210 to $170.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) fell 13% to $0.3661.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) dipped 10.3% to $1,328.74 after Bitcon fell below $62,000.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) fell 9.3% to $16.97.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 8.5% to $827.94.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) fell 8% to $2.6950. Evercore ISI Group upgraded the stock from Underperform to In-Line but lowered its price target from $4.25 to $3.25.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) dipped 7.7% to $208.51 after the price of Bitcoin fell below $62,000.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 5.8% to $119.11. The stock may be pulling back after recent momentum.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39453524/mcdonalds-alphabet-and-2-other-stocks-insiders-are-selling">McDonald&#8217;s, Alphabet And 2 Other Stocks Insiders Are Selling</a>

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and&nbsp;Manufacturing Services for Regenerative Medicine Products

Biotech

Cryoport Partners With Minaris Regenerative Medicine For Cell And Gene Therapies Advancement

WIIM

CryoPort shares are trading lower after the company reported worse-than-expected Q1 financial results.

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $18 price target.

Reiteration

Needham Reiterates Buy on CryoPort, Maintains $18 Price Target

CryoPort Reiterates FY24 Revenue $242M-$252M Vs $245.600M Est.

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.35) by 22.86 percent. This is a 168.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $54.592 million which missed the analyst consensus estimate of $58.760 million by 7.09 percent. This is a 13.09 percent decrease over sales of $62.817 million the same period last year.

Earnings Misses

CryoPort Q1 2024 GAAP EPS $(0.43) Misses $(0.35) Estimate, Sales $54.592M Miss $58.760M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Rosenblatt raised the price target for Apple Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from $189 to $196. Rosenblatt analyst Barton Crockett maintained a Neutral rating. Apple shares rose 2.2% to close at $173.03 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity boosted the price target for Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from $240 to $280. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Coinbase shares rose 8.9% to close at $228.85 on Thursday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) price target from $119 to $122. Rosenblatt analyst Barton Crockett maintained a Buy rating. Live Nation Entertainment shares fell 1.1% to close at $88.27 on Thursday. <a href="https://www.benzinga.com/quote/LYV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho increased the price target for Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) from $110 to $135. Mizuho analyst Brett Linzey maintained a Neutral rating. Xylem shares rose 3.8% to close at $135.99 on Thursday. <a href="https://www.benzinga.com/quote/XYL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) price target from $3,900 to $3,950. B of A Securities analyst Justin Post maintained a Neutral rating. Booking shares rose 1.7% to close at $3,472.91 on Thursday. See how other analysts view this stock.</li>
<li>Wedbush increased The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) price target from $20 to $21. Wedbush analyst Nick Setyan maintained a Neutral rating. Wendy&#8217;s shares gained 1.5% to close at $19.92 on Thursday. <a href="https://www.benzinga.com/quote/WEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Moody&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) from $405 to $414. Baird analyst Jeffrey Meuler maintained an Outperform rating. Moody&#8217;s shares rose 0.9% to close at $376.40 on Thursday. <a href="https://www.benzinga.com/quote/MCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. boosted Texas Roadhouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) price target from $150 to $164. Stephens &amp; Co. analyst Jim Salera maintained an Equal-Weight rating. Texas Roadhouse shares rose 0.5% to close at $157.90 on Thursday. <a href="https://www.benzinga.com/quote/TXRH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel increased Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) price target from $248 to $267. Stifel analyst Benjamin Nolan upgraded the stock from Hold to Buy. Union Pacific shares rose 1.2% to close at $237.69 on Thursday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities slashed Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) price target from $22 to $19. B. Riley Securities analyst Yuan Zhi downgraded the stock from Buy to Neutral. Cryoport shares rose 2.1% to close at $17.16 on Thursday. <a href="https://www.benzinga.com/quote/CYRX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/05/38606493/apple-hershey-and-3-stocks-to-watch-heading-into-friday">Apple, Hershey And 3 Stocks To Watch Heading Into Friday</a>

U.S. stock futures were higher this morning, with the Dow futures gaining over 250 points on Friday.
Shares of Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/STEM/earnings">cut its FY24 revenue guidance</a>.
Stem posted a quarterly loss of 46 cents per share, versus market expectations for a loss of 21 cents per share. The company's quarterly sales came in at $25.47 million missing estimates of $57.11 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Stem shares dipped 18.7% to $1.55 in pre-market trading in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Sprout Social, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) shares declined 25.2% to $36.00 in pre-market trading after the company reported worse-than-expected first-quarter revenue results.</li>
<li>Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) fell 14% to $76.50 pre-market trading after the company reported first-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) shares declined 13% to $20.68 in pre-market trading following first-quarter results.</li>
<li>Adient plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) dipped 12.3% to $26.51 in pre-market trading after the company posted second-quarter results and lowered its FY24 outlook.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares fell 12.1% to $1.52 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) shares declined 10.1% to $121.92 in pre-market trading after the company lowered its full-year guidance.</li>
<li>Open Text Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) shares fell 9.8% to $32.00 in pre-market trading following third-quarter results. BMO Capital downgraded the stock from Outperform to Market Perform and lowered its price target from $50 to $38.</li>
<li>Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) fell 8.3% to $59.81 pre-market trading after the company reported its first-quarter financial results.</li>
<li>Custom Truck One Source, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) fell 7.5% to $4.5304 in pre-market trading after the company reported worse-than-expected first-quarter financial results and cut its FY24 revenue outlook.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) fell 6.7% to $16.00 in pre-market trading. B. Riley Securities analyst Yuan Zhi downgraded CryoPort from Buy to Neutral and lowered the price target from $22 to $19.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) fell 6.4% to $38.57 in pre-market trading following weak first-quarter earnings.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) declined 4.4% to $218.80 in pre-market trading following first-quarter earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/05/38606493/apple-hershey-and-3-stocks-to-watch-heading-into-friday">Apple, Hershey And 3 Stocks To Watch Heading Into Friday</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage</a> here

Stem Reports Downbeat Results, Joins Sprout Social, Cloudflare And Other Big Stocks Moving Lower In Friday's Pre-Market Session

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CryoPort, revealing an average target of $18.4, a high estimate of $21.00, and a low estimate of $17.00. Surpassing the previous average price target of $18.12, the current average has increased by 1.55%.
<img src="https://www.benzinga.com/files/images/story/2024/1714737659_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of CryoPort by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuan Zhi</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CryoPort. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for CryoPort's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into CryoPort's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.13%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -112.45%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CryoPort's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): CryoPort's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.58%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CryoPort's debt-to-equity ratio surpasses industry norms, standing at 0.9. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For CryoPort

B. Riley Securities analyst Yuan Zhi downgrades CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) from Buy to Neutral and lowers the price target from $22 to $19.

B. Riley Securities Downgrades CryoPort to Neutral, Lowers Price Target to $19

5 analysts have shared their evaluations of CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CryoPort, revealing an average target of $18.4, a high estimate of $21.00, and a low estimate of $17.00. Observing a 7.48% increase, the current average has risen from the previous average price target of $17.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1712239247_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive CryoPort is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CryoPort. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CryoPort's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CryoPort's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CryoPort's Background</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Key Indicators: CryoPort's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.13%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -112.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CryoPort's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.19%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.9, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing CryoPort: Insights From 5 Financial Analysts

Jefferies analyst Matthew Stanton assumes CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy rating and raises Price Target to $21.

Initiation

Jefferies Assumes CryoPort at Buy, Raises Price Target to $21

4 analysts have expressed a variety of opinions on CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.75, a high estimate of $19.00, and a low estimate of $17.00. This current average has increased by 3.38% from the previous average price target of $17.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1710511230_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CryoPort's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into CryoPort's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Key Indicators: CryoPort's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, CryoPort faced challenges, resulting in a decline of approximately -5.13% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CryoPort's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -112.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CryoPort's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.9, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBS analyst John Sourbeer maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and raises the price target from $14.5 to $17.

UBS Maintains Neutral on CryoPort, Raises Price Target to $17

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday.
Shares of Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) rose sharply during Thursday&rsquo;s session after the company reported better-than-expected fourth-quarter EPS but missed on revenue, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit <a href="https://www.benzinga.com/quote/BBW/earnings">percentage basis</a>.
Build-A-Bear Workshop shares jumped 15.7% to $29.20 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) shares surged 29.2% to $14.25 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.</li>
<li>VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) shares climbed 22% to $5.45 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>DICK&#39;S Sporting Goods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) gained 14.8% to $215.70 after the company reported strong fourth-quarter results and issued guidance above consensus estimates.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) climbed 14.6% to $6.57 after the company announced that it received a conditional commitment from the U.S. Department of Energy for a $2.26 billion loan under the Advanced Technology Vehicles Manufacturing Loan Program for financing the construction of the processing facilities at Thacker Pass in Nevada.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) rose 11.5% to $126.53 after the company announced a patent litigation settlement with NXP Semiconductors.</li>
<li>Palomar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>) gained 9.4% to $83.24. Jefferies analyst Andrew Andersen upgraded Palomar from Hold to Buy and raised the price target from $78 to $88.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) rose 8.7% to $5.55. Eventbrite announced a $100 million share repurchase program.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) climbed 8.6% to $2.8550.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) surged 8.5% to $15.98.</li>
<li>IHS Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) gained 7.7% to $3.05. TD Cowen analyst Gregory Williams maintained IHS Holding with an Outperform and lowered the price target from $19 to $15.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) gained 6.3% to $18.24 after the company reported February trading metrics.</li>
<li>Cryoport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyrx#NASDAQ">CYRX</a>) gained 6.1% to $15.24. CryoPort recently reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) gained 5.7% to $7.79.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37699845/nerdy-and-3-other-stocks-under-3-insiders-are-buying"> Nerdy And 3 Other Stocks Under $3 Insiders Are Buying</a>

Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick's Sporting Goods And Other Big Stocks Moving Higher On Thursday

Stephens &amp; Co. analyst Jacob Johnson reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Equal-Weight and maintains $17 price target.

Stephens & Co. Reiterates Equal-Weight on CryoPort, Maintains $17 Price Target

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock moved upwards by 25.0% to $0.1. The market value of their outstanding shares is at $4.0 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) stock moved upwards by 19.34% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock moved upwards by 14.97% to $2.38. The company's market cap stands at $303.4 million. </li>
<li>HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) stock increased by 14.04% to $18.62. The company's market cap stands at $3.1 billion. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 13.14% to $0.62. The market value of their outstanding shares is at $22.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares decreased by 14.7% to $0.87 during Wednesday's pre-market session. The market value of their outstanding shares is at $100.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 12.69% to $3.51. The market value of their outstanding shares is at $2.5 million. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares decreased by 10.39% to $14.61. The market value of their outstanding shares is at $715.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 9.9% to $0.82. The company's market cap stands at $40.9 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 8.57% to $5.39. The market value of their outstanding shares is at $117.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 8.21% to $0.04. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

ATNF

CELU

CMPX

Kintara Therapeutics, Inc. - Common Stock

KTRA

NCNA

PIII

RNLX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

CryoPort shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY24 revenue guidance below estimates.

Needham analyst David Saxon maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $19 to $18.

Needham Maintains Buy on CryoPort, Lowers Price Target to $18

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 157.2% to $0.99 during Tuesday's after-market session. The market value of their outstanding shares is at $52.2 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock moved upwards by 39.54% to $0.77. The company's market cap stands at $27.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares moved upwards by 20.19% to $0.5. The market value of their outstanding shares is at $3.6 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock rose 14.56% to $1.73. The company's market cap stands at $4.2 million. As per the press release, Q4 earnings came out today. </li>
<li>MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) shares increased by 14.0% to $4.54. The company's market cap stands at $469.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares rose 13.29% to $4.61. The market value of their outstanding shares is at $2.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 13.9% to $3.46 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 11.85% to $0.04. The market value of their outstanding shares is at $1.1 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock declined by 11.61% to $0.9. The company's market cap stands at $103.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 10.74% to $1.83. The market value of their outstanding shares is at $2.2 million. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock declined by 9.51% to $14.75. The company's market cap stands at $722.2 million. The company's, Q4 earnings came out today. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 8.97% to $0.48. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

MXCT

SCNI

TNON

WORX

12 Health Care Stocks Moving In Tuesday's After-Market Session

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on CryoPort (CYRX – Research Report) and The Middleby (MIDD – ...

Analysts Conflicted on These Industrial Goods Names: CryoPort (CYRX) and The Middleby (MIDD)

CryoPort (CYRX – Research Report), the Industrials sector company, was revisited by a Wall Street analyst today. Analyst Yuan Zhi from B.Riley Fina...

CryoPort: Hold Rating Justified by Mixed Financial Performance and Uncertain CGT Market Prospects

B. Riley cuts Cryoport to neutral, cites top-line growth

CryoPort GAAP EPS of -$0.43 misses by $0.08, revenue of $54.6M misses by $4.17M

Cryoport, Inc. 2024 Q1 - Results - Earnings Call Presentation

Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CryoPort (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyrx-stock-quote/">CYRX</a>) just reported results for the first quarter of 2024.<ul><li>CryoPort reported earnings per share of -43 cents. This was below the analyst estimate for EPS of -35 cents.</li><li>The company reported revenue of $54.59 million.</li><li>This was 7.08% worse than the analyst estimate for revenue of $58.75 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cyrx-stock-earnings-cryoport-for-q1-of-2024/">CYRX Stock Earnings: CryoPort Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYRX Stock Earnings: CryoPort Misses EPS, Misses Revenue for Q1 2024

There's a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Ameresco (AMRC – Research Report), CryoPort (C...

Analysts Are Bullish on These Industrial Goods Stocks: Ameresco (AMRC), CryoPort (CYRX)

Leerink Partners analyst Puneet Souda has reiterated their neutral stance on CYRX stock, giving a Hold rating on May 3. Puneet Souda's rating is ba...

Cautious Hold Rating for CryoPort Amidst Underperformance and Market Headwinds

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on FedEx (FDX – Research Report) and CryoPort (...

Analysts Offer Insights on Industrial Goods Companies: FedEx (FDX) and CryoPort (CYRX)

AMRC

MIDD

SMEGF

Press Releases

Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express

Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services

Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results

Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm

Cryoport Reports First Quarter 2024 Financial Results

Stock News: Johnson Fistel Begins Investigation of Cryoport

Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies


Josh GottheimerHouse (D-NJ)	$1K - $15K	Sale	Oct 15, 2023	Sep 15, 2023	House
Donald BeyerHouse (D-VA)	$1K - $15K	Sale	Mar 03, 2022	Feb 28, 2022	House
Donald BeyerHouse (D-VA)	$1K - $15K	Sale	Feb 01, 2022	Jan 31, 2022	House
Donald BeyerHouse (D-VA)	$1K - $15K	Sale	Feb 01, 2022	Jan 14, 2022	House
Donald BeyerHouse (D-VA)	$1K - $15K	Sale	Feb 01, 2022	Jan 13, 2022	House
Donald BeyerHouse (D-VA)	$1K - $15K	Sale	Oct 01, 2021	Sep 21, 2021	House

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

CryoPort Inc

top performing CYRX trades